胃癌患者CDC25A表达对铂类化疗药物选择的指导作用  

The Role of CDC25A Expression in Guiding the Selection of Platinum-based Chemotherapy Drugs in Patients with Gastric Cancer

作　　者：史猛 孙新宇 王月 SHI Meng;SUN Xin-Yu;WANG Yue(Department of Pathology,Fuxin Mine General Hospital,Liaoning Health Industry Group,Fuxin 123000,China)

机构地区：[1]辽宁健康产业集团阜新矿总医院病理科,辽宁阜新123000

出　　处：《中国药物经济学》2025年第2期44-47,53,共5页China Journal of Pharmaceutical Economics

摘　　要：目的探讨胃癌患者CDC25A表达对铂类化疗药物选择的指导作用。方法选取2020年10月至2023年10月于辽宁健康产业集团阜新矿总医院接受化疗治疗的进展期胃癌患者82例,所有患者均给予CDC25A表达免疫组化检测。将CDC25A表达阳性的患者归为阳性组(n=50),CDC25A表达阴性的患者归为阴性组(n=32)。阳性组患者给予基于奥拉利铂的化疗治疗,阴性组患者给予基于顺铂的化疗治疗,两组均以14 d为1个疗程,连续治疗4个疗程。比较两组患者的治疗效果与安全性。结果阳性组治疗期间白细胞下降、胃肠道反应、肝肾功能损伤、血小板减少、神经毒性毒副反应发生率显著低于阴性组(P<0.05);阳性组治疗总有效率明显高于阴性组(P<0.05);治疗后两组卡氏评分均显著高于治疗前(P<0.05),且阳性组明显高于阴性组(P<0.05)。结论CDC25A参与胃癌的发生与发展,胃癌患者CDC25A表达在铂类化疗药物选择中的应用能提高治疗效果,降低毒副反应,改善患者的生命质量,从而发挥很好的指导治疗作用。Objective To explore the guiding effect of CDC25A expression on the selection of platinum-based chemotherapy drugs in patients with gastric cancer.Methods A total of 82 patients with advanced gastric cancer who received chemotherapy in Fuxinmine General Hospital of Liaoning Health Industry Group from October 2020 to October 2023 were selected.All patients were given immunohistochemical detection of CDC25A expression.Patients with positive CDC25A expression were classified into the positive group(n=50)and those with negative CDC25A expression were classified into the negative group(n=32).Patients in the positive group were given olaliplatin based chemotherapy treatment,and patients in the negative group were given cisplatin based chemotherapy treatment.Both groups were treated for 14 days as a course for 4 consecutive courses.The therapeutic effect and safety of the two groups were compared.Results The incidence of leukopenia,gastrointestinal reaction,liver and kidney function injury,thrombocytopenia,neurotoxicity and side effects in positive group were significantly lower than those in negative group(P<0.05).The total effective rate of positive group was significantly higher than that of negative group(P<0.05).The scores of both groups after treatment were significantly higher than those before treatment(P<0.05),and the positive group was significantly higher than the negative group(P<0.05).Conclusion CDC25A is involved in the occurrence and development of gastric cancer.The application of CDC25A expression in the selection of platinum-based chemotherapy drugs in patients with gastric cancer can improve the therapeutic effect,reduce toxic and side effects,and improve the quality of life of patients,thus playing a good role in guiding treatment.

关 键 词：CDC25A 胃癌 铂类化疗药物 毒副反应 生命质量 奥沙利铂 

分 类 号：R735.2[医药卫生—肿瘤] R979.1[医药卫生—临床医学]